Collectively, PFKFB3i and platinum treatments do not induce differential responses in glycolysis across cancer transformation, thus the cancer-specific synergies between PFKFB3 inhibition and platinum drugs in viability assays are not due to differences in metabolic responses measured. Here, PFKFB3 is linked to cancer.